The first wave of price cuts on the new US Medicare “negotiation” program could reduce the value of section 340B discounts for covered entities by as much as $1 billion per year, an analysis by the 340B Health coalition indicates.
Because 340B providers are able to buy deeply discounted drugs and bill Medicare and commercial payors at prevailing prices, any...





